



## Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

March 8, 2022

LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 17, 2022. Iraj Ali, Chief Executive Officer, will present an overview of the company and pipeline on Tuesday, March 15, 2022, at 8:00 am ET / 12:00 pm UK.

A live and archived webcast of the presentation will be available in the [Events & Presentations](#) section of the [Achilles website](#).

### About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

### Contacts:

#### Investors:

Achilles Therapeutics  
Lee M. Stern, VP, IR & External Communications  
[L.stern@achillestx.com](mailto:L.stern@achillestx.com)

LifeSci Advisors  
John Mullaly  
[jmullaly@lifesciadvisors.com](mailto:jmullaly@lifesciadvisors.com)

#### Media:

**Consilium Strategic Communications**  
Mary-Jane Elliott, Sukaina Viridi, Melissa Gardiner  
+44 (0) 203 709 5000  
[achillestx@consilium-comms.com](mailto:achillestx@consilium-comms.com)